{"protocolSection": {"identificationModule": {"nctId": "NCT02256345", "orgStudyIdInfo": {"id": "01340"}, "organization": {"fullName": "University of Pennsylvania", "class": "OTHER"}, "briefTitle": "Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF", "officialTitle": "Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF"}, "statusModule": {"statusVerifiedDate": "2017-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-01"}, "primaryCompletionDateStruct": {"date": "2016-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-09-30", "studyFirstSubmitQcDate": "2014-09-30", "studyFirstPostDateStruct": {"date": "2014-10-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-06-14", "resultsFirstSubmitQcDate": "2017-08-30", "resultsFirstPostDateStruct": {"date": "2017-10-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-08-30", "lastUpdatePostDateStruct": {"date": "2017-10-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Pennsylvania", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will be performed to determine the safety, tolerability, and dose-response to inorganic nitrate on exercise capacity in HFpEF. There are two primary goals for this study:\n\n1. Determine the population-specific pharmacokinetics and dose of KNO3 that can be safely given to subjects with HFpEF.\n2. Determine if there is a dose-response effect of nitrate supplementation on exercise capacity, evidenced by peak oxygen consumption (peak VO2), and physiologic adaptations to exercise.", "detailedDescription": "This study randomized subjects to either placebo (n=3) or KNO3 (n=9) given a sequential dosing regimen: 6 mmol twice daily for 1 week followed by dose escalation to 6 mmol thrice daily for 1 week). Although a primary goal of the study was to assess the safety of KNO3 and within-group changes in various end points in KNO3-treated subjects, a small number of placebo-treated (PB, n=3) subjects were included only to assess for any potential training effect on repeated exercise and Kansas City Cardiomyopathy Questionnaire (KCCQ) measurements. Potassium chloride, given in equivalent doses, was used as the PB to account for differences in blood pressure or flow that could be attributed to potassium.\n\nThe study was initially designed to be single-blinded to allow the principal investigator to be aware of arm allocation because of potential concerns for methemoglobinemia with drug administration. One investigator, who was the primary investigator responsible for supervising all visits and measurements during the study, remained blinded to treatment allocation throughout the entirety of the study. All physiological and imaging data were analyzed in a double-blind manner."}, "conditionsModule": {"conditions": ["Heart Failure", "Diastolic Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 12, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "KNO3 active comparator", "type": "ACTIVE_COMPARATOR", "description": "KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated", "interventionNames": ["Drug: KNO3"]}, {"label": "KCl placebo comparator", "type": "PLACEBO_COMPARATOR", "description": "KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated", "interventionNames": ["Drug: KCl"]}], "interventions": [{"type": "DRUG", "name": "KNO3", "description": "Active Comparator", "armGroupLabels": ["KNO3 active comparator"], "otherNames": ["Potassium Nitrate"]}, {"type": "DRUG", "name": "KCl", "description": "Placebo Comparator", "armGroupLabels": ["KCl placebo comparator"], "otherNames": ["Potassium Chloride"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Peak Oxygen Uptake (VO2) From Baseline Upto 1 Week of Administration for Each Dose", "description": "Peak oxygen uptake (VO2) defined as the average value obtained during the last 30 seconds of exercise.", "timeFrame": "Baseline, end of week 1, end of week 2"}], "secondaryOutcomes": [{"measure": "Change in Vasodilatory Reserve for Each Dose", "description": "Percent change in peak vascular resistance from rest to peak exercise", "timeFrame": "Baseline, end of week 1, end of week 2"}, {"measure": "Change in Mitochondrial Oxidative Capacity for Each Dose", "description": "Percent change in oxidative capacity (oxyhemoglobin levels) before and after occlusion", "timeFrame": "Baseline, end of week 1, end of week 2"}, {"measure": "Change in Aortic Augmentation Index", "description": "Percent change in augmentation index, whereas augmentation index at each time point (visit) is defined as the amplitude of the second peak to the first peak of the aortic pulse wave form multiplied by 100: augmentation index = (P2/P1)\u00d7100.", "timeFrame": "Baseline, end of week 1, end of week 2"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. NYHA Class II-III symptoms.\n2. LV EF \\> 50%.\n3. Stable medical therapy for at least 1 month.\n4. Evidence of significant diastolic dysfunction, meeting the European Society of Echocardiography criteria for HFpEF.\n\nExclusion Criteria\n\n1. Any rhythm other than sinus with native conduction.\n2. Inability to exercise.\n3. Moderate or greater valvular disease.\n4. Hypertrophic, infiltrative, or inflammatory cardiomyopathy.\n5. Pericardial disease.\n6. Current angina.\n7. Acute coronary syndrome or coronary intervention within the past 2 months.\n8. Primary pulmonary arteriopathy.\n9. Clinically significant lung disease.\n10. Ischemia on stress testing without subsequent revascularization.\n11. Treatment with phosphodiesterase inhibitors that cannot be withheld.\n12. Treatment with organic nitrates or allopurinol.\n13. Significant liver disease impacting synthetic function or volume control.\n14. Poor echocardiographic windows.\n15. eGFR \\< 30 mL/min/m2 or Cr \\>2.5.\n16. Current smoking.\n17. Alcohol dependency.\n18. History of Barret's esophagus.\n19. G6PD deficiency\n20. Methemoglobinemia - baseline methemoglobin level \\>3% prior to any study medication.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Julio A Chirinos, MD", "affiliation": "University of Pennsylvania", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Hospital of the University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}]}, "referencesModule": {"references": [{"pmid": "27927683", "type": "DERIVED", "citation": "Zamani P, Tan V, Soto-Calderon H, Beraun M, Brandimarto JA, Trieu L, Varakantam S, Doulias PT, Townsend RR, Chittams J, Margulies KB, Cappola TP, Poole DC, Ischiropoulos H, Chirinos JA. Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction. Circ Res. 2017 Mar 31;120(7):1151-1161. doi: 10.1161/CIRCRESAHA.116.309832. Epub 2016 Dec 7."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Randomized to KNO3", "description": "KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated.\n\nActive Comparator: Potassium Nitrate (KNO3)"}, {"id": "FG001", "title": "Randomized to KCl", "description": "KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated.\n\nPlacebo Comparator: Potassium Chloride (KCl)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Randomized to KNO3", "description": "KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated\n\nActive Comparator: Potassium Nitrate"}, {"id": "BG001", "title": "Randomized to KCl", "description": "KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if tolerating well.\n\nPlacebo Comparator: Potassium Chloride"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "12"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "62.4", "spread": "5.5"}, {"groupId": "BG001", "value": "62.7", "spread": "8.0"}, {"groupId": "BG002", "value": "62.5", "spread": "5.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Race, n (%)", "categories": [{"title": "White", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "8"}]}, {"title": "Black", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "New York Heart Association Heart failure classification (NYHA Class) n (%)", "description": "Class II- Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).\n\nClass III- Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Class II", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "10"}]}, {"title": "Class III", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Body Mass Index, kg/m^2, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.4", "spread": "6.3"}, {"groupId": "BG001", "value": "37.4", "spread": "9.9"}, {"groupId": "BG002", "value": "34.4", "spread": "7.0"}]}]}]}, {"title": "Number of Obese Participants, n(%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "8"}]}]}]}, {"title": "Number of Hypertensive Participants, n(%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "12"}]}]}]}, {"title": "Number of Participants with Hyperlipidemia, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "10"}]}]}]}, {"title": "Number of Participants with Coronary Artery Disease, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Number of Participants with History of atrial fibrillation, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Number of Participants with Diabetes Mellitus, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Number of Participants with Obstructive sleep apnea, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "Number of Participants with Current Continuous Positive Airway Pressure (CPAP) use, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Number of Participants with Obstructive lung disease, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Number of Participants on Beta-blockers, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "9"}]}]}]}, {"title": "Number of Participants onACEI/ARB, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "9"}]}]}]}, {"title": "Number of Participants on Mineralocorticoid receptor antagonists, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Number of Participants on Calcium-channel blockers, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Number of Participants on Loop diuretics, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "9"}]}]}]}, {"title": "Number of Participants on Thiazide diuretic, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Number of Participants on Statin, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Estimated Glomerular Filtration Rate (eGFR), mL/min per 1.73m^2, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min per 1.73m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "71.0", "spread": "14.1"}, {"groupId": "BG001", "value": "64.7", "spread": "5.9"}, {"groupId": "BG002", "value": "69.4", "spread": "12.6"}]}]}]}, {"title": "Estimated Glomerular Filtration Rate (eGFR) <60 mL/min per 1.73m^2, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "N-terminal pro-brain natriuretic peptide (NT-proBNP), pg/ml, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pg/ml", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "108.3", "spread": "94.7"}, {"groupId": "BG001", "value": "119", "spread": "87.0"}, {"groupId": "BG002", "value": "111", "spread": "89.0"}]}]}]}, {"title": "Number of Participants with high N-terminal pro-brain natriuretic peptide (NT-proBNP), pg/ml, n (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Hemoglobin, g/dL, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "13.6", "spread": "0.8"}, {"groupId": "BG001", "value": "13.5", "spread": "1.0"}, {"groupId": "BG002", "value": "13.6", "spread": "0.8"}]}]}]}, {"title": "Methemoglobin, %, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent of total hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.0", "spread": "0.2"}, {"groupId": "BG001", "value": "1.0", "spread": "0.5"}, {"groupId": "BG002", "value": "1.0", "spread": "0.3"}]}]}]}, {"title": "Left Ventricular (LV) mass,g, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "174.43", "spread": "77.09"}, {"groupId": "BG001", "value": "165.98", "spread": "19.27"}, {"groupId": "BG002", "value": "172.32", "spread": "66.36"}]}]}]}, {"title": "Left Ventricular (LV) mass index, g/m^2, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "79.78", "spread": "26.01"}, {"groupId": "BG001", "value": "76.18", "spread": "7.33"}, {"groupId": "BG002", "value": "78.88", "spread": "22.46"}]}]}]}, {"title": "Relative wall thickness, mean (SD)", "description": "The ratio of twice LV diastolic posterior wall thickness to left ventricular end-diastolic dimension", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ratio", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.47", "spread": "0.09"}, {"groupId": "BG001", "value": "0.46", "spread": "0.09"}, {"groupId": "BG002", "value": "0.47", "spread": "0.09"}]}]}]}, {"title": "Mitral early inflow velocity (E), cm/s, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm/s", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "74.53", "spread": "24.75"}, {"groupId": "BG001", "value": "85.73", "spread": "7.04"}, {"groupId": "BG002", "value": "77.33", "spread": "21.91"}]}]}]}, {"title": "Mitral atrial inflow velocity (E), cm/s, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm/s", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.74", "spread": "20.06"}, {"groupId": "BG001", "value": "88.61", "spread": "21.28"}, {"groupId": "BG002", "value": "75.21", "spread": "20.99"}]}]}]}, {"title": "Septal tissue doppler early velocity (e'), mm/s, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm/s", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.64", "spread": "12.45"}, {"groupId": "BG001", "value": "93.71", "spread": "28.65"}, {"groupId": "BG002", "value": "76.41", "spread": "19.26"}]}]}]}, {"title": "Septal E/e' ratio, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ratio", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.70", "spread": "3.76"}, {"groupId": "BG001", "value": "9.60", "spread": "2.39"}, {"groupId": "BG002", "value": "10.42", "spread": "3.40"}]}]}]}, {"title": "Left atrial volume index, mL/m^2, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.20", "spread": "7.87"}, {"groupId": "BG001", "value": "29.38", "spread": "5.33"}, {"groupId": "BG002", "value": "27.74", "spread": "7.15"}]}]}]}, {"title": "Left ventricular ejection fraction, %, mean (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "% (stroke volume/ end-diastolic vol)x100", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "65.84", "spread": "7.74"}, {"groupId": "BG001", "value": "59.41", "spread": "13.66"}, {"groupId": "BG002", "value": "64.23", "spread": "9.27"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Peak Oxygen Uptake (VO2) From Baseline Upto 1 Week of Administration for Each Dose", "description": "Peak oxygen uptake (VO2) defined as the average value obtained during the last 30 seconds of exercise.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L/min", "timeFrame": "Baseline, end of week 1, end of week 2", "groups": [{"id": "OG000", "title": "Randomized to KNO3", "description": "KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated\n\nActive Comparator: Potassium Nitrate"}, {"id": "OG001", "title": "Randomized to KCl", "description": "KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if tolerating well.\n\nPlacebo Comparator: Potassium Chloride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "3"}]}], "classes": [{"title": "Baseline Viist", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.16", "lowerLimit": "1.13", "upperLimit": "1.19"}, {"groupId": "OG001", "value": "1.49", "lowerLimit": "1.43", "upperLimit": "1.54"}]}]}, {"title": "End of week 1 visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.20", "lowerLimit": "1.17", "upperLimit": "1.24"}, {"groupId": "OG001", "value": "1.44", "lowerLimit": "1.39", "upperLimit": "1.49"}]}]}, {"title": "End of week 2 visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.20", "lowerLimit": "1.17", "upperLimit": "1.23"}, {"groupId": "OG001", "value": "1.44", "lowerLimit": "1.39", "upperLimit": "1.50"}]}]}]}, {"type": "SECONDARY", "title": "Change in Vasodilatory Reserve for Each Dose", "description": "Percent change in peak vascular resistance from rest to peak exercise", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "%change in peak vascular resistance", "timeFrame": "Baseline, end of week 1, end of week 2", "groups": [{"id": "OG000", "title": "Randomized to KNO3", "description": "KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated\n\nActive Comparator: Potassium Nitrate"}, {"id": "OG001", "title": "Randomized to KCl", "description": "KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if tolerating well.\n\nPlacebo Comparator: Potassium Chloride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "3"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-25.6", "lowerLimit": "-40.9", "upperLimit": "-10.4"}, {"groupId": "OG001", "value": "-25.8", "lowerLimit": "-31.4", "upperLimit": "-20.3"}]}]}, {"title": "End of week 1 visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.1", "lowerLimit": "-43.6", "upperLimit": "-10.5"}, {"groupId": "OG001", "value": "-30.6", "lowerLimit": "-36.2", "upperLimit": "-25.1"}]}]}, {"title": "End of week 2 visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "-34.2", "lowerLimit": "-49.4", "upperLimit": "-18.9"}, {"groupId": "OG001", "value": "-20.0", "lowerLimit": "-24.2", "upperLimit": "-15.8"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mitochondrial Oxidative Capacity for Each Dose", "description": "Percent change in oxidative capacity (oxyhemoglobin levels) before and after occlusion", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change in oxidative capacity", "timeFrame": "Baseline, end of week 1, end of week 2", "groups": [{"id": "OG000", "title": "Randomized to KNO3", "description": "KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated\n\nActive Comparator: Potassium Nitrate"}, {"id": "OG001", "title": "Randomized to KCl", "description": "KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if tolerating well.\n\nPlacebo Comparator: Potassium Chloride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "3"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "63.2", "lowerLimit": "47.6", "upperLimit": "78.8"}, {"groupId": "OG001", "value": "106.5", "lowerLimit": "59.2", "upperLimit": "153.7"}]}]}, {"title": "End of week 1 visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "59.2", "lowerLimit": "42.1", "upperLimit": "76.2"}, {"groupId": "OG001", "value": "110.4", "lowerLimit": "63.2", "upperLimit": "157.7"}]}]}, {"title": "End of Week 2 visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "62.2", "lowerLimit": "46.6", "upperLimit": "77.7"}, {"groupId": "OG001", "value": "45.4", "lowerLimit": "5.0", "upperLimit": "85.8"}]}]}]}, {"type": "SECONDARY", "title": "Change in Aortic Augmentation Index", "description": "Percent change in augmentation index, whereas augmentation index at each time point (visit) is defined as the amplitude of the second peak to the first peak of the aortic pulse wave form multiplied by 100: augmentation index = (P2/P1)\u00d7100.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change in augumentation index", "timeFrame": "Baseline, end of week 1, end of week 2", "groups": [{"id": "OG000", "title": "Randomized to KNO3", "description": "KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated\n\nActive Comparator: Potassium Nitrate"}, {"id": "OG001", "title": "Randomized to KCl", "description": "KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if tolerating well.\n\nPlacebo Comparator: Potassium Chloride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "3"}]}], "classes": [{"title": "Baseline visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "lowerLimit": "-5.4", "upperLimit": "11.4"}, {"groupId": "OG001", "value": "-2.3", "lowerLimit": "-11.5", "upperLimit": "6.8"}]}]}, {"title": "End of week 1 visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.4", "lowerLimit": "-13.1", "upperLimit": "2.4"}, {"groupId": "OG001", "value": "-11.9", "lowerLimit": "-23.5", "upperLimit": "-0.2"}]}]}, {"title": "End of week 2 visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.1", "lowerLimit": "-14.9", "upperLimit": "0.6"}, {"groupId": "OG001", "value": "-0.2", "lowerLimit": "-9.4", "upperLimit": "9.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse events were collected at every visit. There are a total of three visits that are 1 week apart.", "description": "All adverse events were non serious so they are reported under Other Adverse Events", "eventGroups": [{"id": "EG000", "title": "Randomized to KNO3", "description": "KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated\n\nActive Comparator: Potassium Nitrate", "deathsNumAffected": 0, "deathsNumAtRisk": 9, "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 5, "otherNumAtRisk": 9}, {"id": "EG001", "title": "Randomized to KCl", "description": "KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if tolerating well.\n\nPlacebo Comparator: Potassium Chloride", "deathsNumAffected": 0, "deathsNumAtRisk": 3, "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 1, "otherNumAtRisk": 3}], "otherEvents": [{"term": "Any side effect", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}]}, {"term": "GI symptoms", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Includes GI upset, nausea, vomiting, flatulence", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}]}, {"term": "Mild lower extremity edema", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}]}, {"term": "Tooth infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}]}, {"term": "Fatigue", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "* Small sample size\n* Serial blood draws, which caused a decrease in hemoglobin concentration, which may have constrained the increase in VO2,peak and reduced the magnitude of the improvement in exercise capacity and quality of life."}, "certainAgreement": {"piSponsorEmployee": true, "restrictiveAgreement": false}, "pointOfContact": {"title": "Julio Chirinos", "organization": "UPenn", "email": "julio.chirinos@uphs.upenn.edu", "phone": "2158235800"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000054144", "term": "Heart Failure, Diastolic"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27580", "name": "Heart Failure, Diastolic", "asFound": "Diastolic Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}